Stroke Prevention: Managing Modifiable Risk Factors

被引:30
作者
Di Legge, Silvia [1 ]
Koch, Giacomo [1 ,2 ]
Diomedi, Marina [1 ]
Stanzione, Paolo [1 ,2 ]
Sallustio, Fabrizio [1 ,2 ]
机构
[1] Univ Tor Vergata, Dept Neurosci, Stroke Unit, Viale Oxford 81, I-00133 Rome, Italy
[2] IRCCS, Santa Lucia Fdn, Viale Ardeatina 306, I-00134 Rome, Italy
关键词
D O I
10.1155/2012/391538
中图分类号
R6 [外科学];
学科分类号
1002 [临床医学]; 100210 [外科学];
摘要
Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50% of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of recurrent stroke and other vascular events. The use of antiplatelets and statins has been shown to reduce the risk of recurrent stroke and other vascular events. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are indicated in stroke prevention because they also promote vascular health. Effective secondary-prevention strategies for selected patients include carotid revascularization for high-grade carotid stenosis and vitamin K antagonist treatment for atrial fibrillation. The results of recent clinical trials investigating new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) clearly indicate alternative strategies in stroke prevention for patients with atrial fibrillation. This paper describes the current landscape and developments in stroke prevention with special reference to medical treatment in secondary prevention of ischemic stroke.
引用
收藏
页数:15
相关论文
共 120 条
[1]
Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation A Meta-analysis [J].
Agarwal, Shikhar ;
Hachamovitch, Rory ;
Menon, Venu .
ARCHIVES OF INTERNAL MEDICINE, 2012, 172 (08) :623-631
[2]
Oral anticoagulants versus antiplatelet therapy for preventing stoke in patients with non-valvular artial fibrillation and no history of stroke or transient ischemic attacks [J].
Aguilar, M., I ;
Hart, R. ;
Pearce, L. A. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03)
[3]
Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation - Pooled analysis of SPORTIF III and V clinical trials [J].
Akins, Paul T. ;
Feldman, Harvey A. ;
Zoble, Robert G. ;
Newman, David ;
Spitzer, Stefan G. ;
Diener, Hans-Christoph ;
Albers, Gregory W. .
STROKE, 2007, 38 (03) :874-880
[4]
Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
[5]
Statins in stroke prevention and carotid atherosclerosis -: Systematic review and up-to-date meta-analysis [J].
Amarenco, P ;
Labreuche, J ;
Lavallée, P ;
Touboul, PJ .
STROKE, 2004, 35 (12) :2902-2909
[6]
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[7]
Angelopoulos J, 2009, ARCH MED SCI, V5, P347
[8]
[Anonymous], 1991, JAMA, V265, P3255
[9]
[Anonymous], 2001, JAMA, V285, P1571
[10]
Executive Summary: Standards of Medical Care in Diabetes-2009 [J].
不详 .
DIABETES CARE, 2009, 32 :S6-S12